<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="29216">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02726386</url>
  </required_header>
  <id_info>
    <org_study_id>ND0612H-012</org_study_id>
    <nct_id>NCT02726386</nct_id>
  </id_info>
  <brief_title>A Clinical Study Investigating Long Term Safety of ND0612, a Solution of Levodopa/Carbidopa Administered as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease</brief_title>
  <official_title>A Multicenter, International, Open-label, Safety Study of ND0612, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeuroDerm Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeuroDerm Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, international, open-label, safety study of ND0612, a solution of
      levodopa/carbidopa (LD/CD) delivered via a pump system as a continuous SC infusion in
      subjects with advanced Parkinson's Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase open-label safety study will be conducted in approximately 100 subjects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the long term safety (systemic and local) and tolerability of continuous subcutaneous infusion of ND0612 by adverse events, vital signs, local tolerability</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>ND0612 (Levodopa/Carbidopa solution) - Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regimen 1 of ND0612 (LD/CD solution) continuous subcutaneous infusion over 24 hrs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ND0612 (Levodopa/Carbidopa solution) - Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regimen 2 of ND0612 (LD/CD solution) continuous subcutaneous for over 14-16 hrs .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ND0612</intervention_name>
    <description>ND0612, a solution of levodopa/carbidopa (LD/CD) delivered continuously subcutaneously (SC) via an infusion pump system</description>
    <arm_group_label>ND0612 (Levodopa/Carbidopa solution) - Regimen 1</arm_group_label>
    <arm_group_label>ND0612 (Levodopa/Carbidopa solution) - Regimen 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female ,Parkinson's disease subjects of any race aged 30 to 85 years .

          -  PD diagnosis consistent with the UK Brain Bank Criteria.

          -  Modified Hoehn &amp; Yahr scale in &quot;ON&quot; state of stage â‰¤3.

          -  Taking at least 4 doses/day of Levodopa (or at least 3 doses/day of Rytary) and
             taking, or have attempted to take, at least 1 other Parkinson's disease treatment for
             at least 30 days in the previous year.

          -  Subjects must be stable on their anti-Parkinson's disease medications for at least 30
             days before Day 1.

          -  Subjects may have had prior exposure to Sub Cutaneous apomorphine injections/infusion
             but must have stopped administration at least 4 weeks before the screening visit.
             Treatment with apomorphine is prohibited during the entire ND0612 treatment period.

          -  Must have a minimum of 2 hours of &quot;OFF&quot; time per day with predictable early morning
             &quot;OFF&quot; periods as estimated by the subject.

          -  Must have predictable and well defined early morning &quot;OFF&quot; periods with a good
             response to Levodopa for treatment of the early morning &quot;OFF&quot; in the judgement of the
             investigator.

          -  Mini Mental State Examination (MMSE) score &gt;26.

          -  No clinically significant medical, psychiatric or laboratory abnormalities which the
             investigator judges would be unsafe or non-compliant in the study.

          -  Female subjects must be surgically sterile (hysterectomy, bilateral oophorectomy, or
             tubal ligation), postmenopausal (defined as cessation of menses for at least 1 year),
             or willing to practice a highly effective method of contraception. All female
             participants must be non-lactating and non-pregnant and have a negative urine
             pregnancy test at Screening and at Baseline. Female subjects of childbearing
             potential must practice a highly effective method of contraception ( oral
             contraceptives plus a barrier method of birth control [condoms with contraceptive
             foams, diaphragms with contraceptive jelly], intrauterine devices, partner with
             vasectomy), 1 month before enrollment, for the duration of the study, and 3 months
             after the last dose of study drug.

          -  Willing and able to administer the subcutaneous infusion alone or with the assistance
             of a study partner after a screening period of 28 days and willing and able to comply
             with study requirements.

        Exclusion Criteria:

        For Cohort 1 and Cohort 2, the following exclusion criterion applies:

          -  Previously unable to tolerate ND0612 and/or have experienced intolerable adverse drug
             reactions associated with its use, regardless of the dosing regimen administered.

        For Cohort 2, the following exclusion criteria apply:

          -  Atypical or secondary parkinsonism.

          -  Acute psychosis or hallucinations in past 6 months.

          -  Any relevant medical, surgical, or psychiatric condition, laboratory value, or
             concomitant medication which, in the opinion of the Investigator makes the subject
             unsuitable for study entry or potentially unable to complete all aspects of the
             study.

          -  Prior neurosurgical procedure for Parkinson's disease, or duodopa treatment.

          -  Subjects with a history of drug abuse or alcoholism within the past 12 months.

          -  Clinically significant ECG rhythm abnormalities.

          -  Renal or liver dysfunction that may alter drug metabolism including: serum creatinine
             &gt;1.3 mg/dL, serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT)
             &gt;2 x upper limit of normal (ULN), total serum bilirubin &gt;2.5 mg/dL.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yael Ullmann</last_name>
    <phone>+972-8-9462729</phone>
    <email>ullmann.y@neuroderm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yael Cohen</last_name>
    <phone>+972-8-9462729</phone>
    <email>yael@neuroderm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Neuro Pain Medical Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Perminder Bhatia</last_name>
      <phone>559-437-9700</phone>
      <email>neuro736@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Isha Monga Harpreet</last_name>
      <phone>559-347-9700</phone>
      <email>Ishaneuro2010@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Movement Disorders Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113-2776</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajeev Kumar, Dr.</last_name>
      <phone>303-357-5455</phone>
      <email>rajeev_kumar@msn.com</email>
    </contact>
    <contact_backup>
      <last_name>Peggy Hugger</last_name>
      <phone>303 867 5468</phone>
      <email>phugger@kumarneuro.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>MD Clinical</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Safirstein, Dr.</last_name>
      <phone>954-455-5757</phone>
      <email>bsafirstein@mdclinical.org</email>
    </contact>
    <contact_backup>
      <last_name>William Torres</last_name>
      <phone>954-455-5757</phone>
      <email>wtorres@mdclinical.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Infinity Clinical Research, LLC</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Ginsberg, Dr.</last_name>
      <phone>954-366-0277</phone>
      <email>pginsberg@infinityclinicalresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Becky Nembhard</last_name>
      <phone>954-366-0277</phone>
      <email>rnembhard@infinityclinicalresearch.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Neurology Associates, PA</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751-4723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaldo Isa, Dr.</last_name>
      <phone>407-647-5996</phone>
      <phone_ext>236</phone_ext>
      <email>aisa@cfl.rr.com</email>
    </contact>
    <contact_backup>
      <last_name>Kelly Holley</last_name>
      <phone>407-647-5996</phone>
      <phone_ext>204</phone_ext>
      <email>neurologyassoc@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Parkinsons Disease Treatment Center of Southwest Florida</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33980</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramon Gil, Dr.</last_name>
      <phone>941-743-4987</phone>
      <email>drgil@parkinsonsfl.com</email>
    </contact>
    <contact_backup>
      <last_name>Judy Seymour</last_name>
      <phone>941-743-4987</phone>
      <email>judys@parkinsonsfl.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Suncoast Neuroscience Associates</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33713-8844</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Vasquez, Dr.</last_name>
      <phone>727-202-2623</phone>
      <email>abvmd@aol.com</email>
    </contact>
    <contact_backup>
      <last_name>Ian Lever</last_name>
      <phone>727-202-2640</phone>
      <email>ilever@suncoastneuroresearch.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Infinity Clinical Research, LLC</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barry Cutler, Dr.</last_name>
      <phone>954-475-8171</phone>
      <email>bcutler@infinityclinicalresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Fanny Gully</last_name>
      <phone>954-475-8171</phone>
      <email>fgully@infinityclinicalresearch.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanya Simuni, Dr.</last_name>
      <email>tsimuni@nmff.org</email>
    </contact>
    <contact_backup>
      <last_name>Karen Williams</last_name>
      <phone>312 503 5645</phone>
      <email>k-williams8@northwestern.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>QUEST Research Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Ellenbogen, Dr.</last_name>
      <phone>248-957-8940</phone>
      <email>aaron@questri.com</email>
    </contact>
    <contact_backup>
      <last_name>Dolly Niles</last_name>
      <phone>248-957-8940</phone>
      <email>dolly@questri.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Pyramid Clinical Research</name>
      <address>
        <city>Somerset</city>
        <state>New Jersey</state>
        <zip>08873-3448</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Greenberg, Dr.</last_name>
      <phone>844-255-1721</phone>
      <email>Jgreenberg@Pyramidcr.com</email>
    </contact>
    <contact_backup>
      <last_name>Jillian Long</last_name>
      <phone>844-255-1721</phone>
      <email>jillian@pyramidcr.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Espay, Dr.</last_name>
      <phone>513-558-4035</phone>
      <email>alberto.espay@uc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Molly Winters</last_name>
      <phone>513-558-0269</phone>
      <email>winteme@ucmail.uc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Movement Disorder Clinic of Oklahoma</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Klos</last_name>
      <phone>918-392-4530</phone>
      <email>Kevin.klos@mdcok.com</email>
    </contact>
    <contact_backup>
      <last_name>Shannon Gurley</last_name>
      <phone>918-392-4530</phone>
      <email>Shannon.gurley@mdcok.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Synergy Trials</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cletus Aralu, Dr.</last_name>
      <email>cletus.aralu.neuro@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ritha Khleang</last_name>
      <phone>804-405-4140</phone>
      <email>ritha.khleang.rva@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Werner Poewe, Prof.</last_name>
      <phone>0043 512 504 23850</phone>
      <email>werner.poewe@i-med.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Katarzyna Wachowicz</last_name>
      <phone>0043 512 504 23850</phone>
      <email>katarzyna.wachowicz@i-med.ac.at</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kliniken Beelitz GmbH</name>
      <address>
        <city>Beelitz Heilstaetten</city>
        <zip>14547</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Ebersbach, Prof.</last_name>
      <phone>0049 33204-22781</phone>
      <email>ebersbach@kliniken-beelitz.de</email>
    </contact>
    <contact_backup>
      <last_name>Karl Rowena</last_name>
      <phone>0049 33204-22781</phone>
      <email>karl@kliniken-beelitz.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Djaldetti, Prof.</last_name>
      <phone>972-3-9377154</phone>
      <email>ruthdjal@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Yaniv Rodity, Mr.</last_name>
      <phone>972-3-6528734</phone>
      <email>YAr@clalit.org.il</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>56520</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Hassin, Prof.</last_name>
      <phone>972-3-5905293</phone>
      <email>sharon.hassin@sheba.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Patricia Federman</last_name>
      <phone>972-3-5304931</phone>
      <email>Patricia.Federman@sheba.health.gov.il</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanya Gurevich, Dr.</last_name>
      <phone>972-3-6974912</phone>
      <email>tanyag@tlvmc.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Angel Migirov, M.</last_name>
      <phone>972-3-6973001</phone>
      <email>angelm@tlvmc.gov.il</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Foundation</name>
      <address>
        <city>Chieti Scalo</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Onofrj, prof.</last_name>
      <phone>0039 0871 358525</phone>
      <email>onofrj@unich.it</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Astrid, Prof.</last_name>
      <phone>0039 3286537740</phone>
      <email>athomas@unich.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>AOU Pisa</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ubaldo Bonuccelli, Prof.</last_name>
      <phone>0039 050993604</phone>
      <email>u.bonuccelli@med.unipi.it</email>
    </contact>
    <contact_backup>
      <last_name>Pierangela Riani, Ms.</last_name>
      <phone>0039 3403134789</phone>
      <email>p.riani@ao-pisa.toscana.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>IRCCS San Raffaele Pisana</name>
      <address>
        <city>Rome</city>
        <zip>00163</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrizio Stocchi, Prof.</last_name>
      <phone>0039 06 52252311</phone>
      <email>fabrizio.stocchi@sanraffaele.it</email>
    </contact>
    <contact_backup>
      <last_name>Miriam Casali</last_name>
      <phone>0039 06 52252311</phone>
      <email>miriam.casali@sanraffaele.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>IRCCS Hospital San Camillo Venice</name>
      <address>
        <city>Venice</city>
        <zip>30126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelo Antonini, Prof.</last_name>
      <phone>0039 4122073765</phone>
      <email>angelo3000@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>NicolÃ² Anesa, Mr.</last_name>
      <phone>0039 0412207505</phone>
      <email>Nicolo.anesa@ospedalesancamillo.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>February 23, 2017</lastchanged_date>
  <firstreceived_date>March 29, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Levodopa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
